Discontinuation of RAAS Inhibition in Children with Advanced CKD

van den Belt S. M., Heerspink H. J. L., Kirchner M., Gracchi V., Thurn-Valsassina D., Bayazit A., ...Daha Fazla

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, cilt.15, sa.5, ss.625-632, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2215/cjn.09750819
  • Dergi Adı: CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.625-632
  • Anahtar Kelimeler: RAAS inhibition, pediatric nephrology, chronic renal disease, Hyperkalemia, albuminuria, Renin-Angiotensin System, creatinine, blood pressure, Potassium, Prospective Studies, Follow-Up Studies, glomerular filtration rate, Renal Insufficiency, Chronic, Cohort Studies, Blood Pressure Determination, hypotension, Comorbidity, Acceleration, TYPE-2 DIABETIC-NEPHROPATHY, RENIN-ANGIOTENSIN SYSTEM, RENAL OUTCOMES, KIDNEY-DISEASE, BLOOD-PRESSURE, PROTEINURIA, TELMISARTAN, WITHDRAWAL, REDUCTION, LOSARTAN
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background and objectives Although renin-angiotensin-aldosterone system inhibition (RAASi) is a cornerstone in the treatment of children with CKD, it is sometimes discontinued when kidney function declines. We studied the reasons of RAASi discontinuation and associations between RAASi discontinuation and important risk markers of CKD progression and on eGFR decline in the Cardiovascular Comorbidity in Children with CKD study.